JGL plans, in collaboration with companies Chr. Hansen and Urex Biotech, to launchtheLactogyn preparation onto the market, a preparation intended for the regeneration and maintenance of vaginal microflora.
Lactogyn capsules contain a unique combination of two probiotic strains which are clinically proven, for the first time in the world, to be able to populate the vaginal tract after oral administration and thus have a positive effect on a woman’s urogenital health.
Lactogyn will be available in pharmacies in Croatia as of October this year.
Vaginal microflora is a natural defence mechanism against harmful bacteria and fungi population. It is clinically proven that women with a vaginal microflora disorder have a higher risk of urogenital infections. Unpleasant symptoms of such infections can include burning sensations, itching in the intimate area and vaginal discharge. The risk is particularly high for women taking antibiotics, who are exposed to stress, spermicide and frequently change partners. Some other conditions we cannot influence, such as the menopause or diabetes, can result in an imbalance of vaginal microflora.
Lactogyn contains unique probiotic strains Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 which are a result of 20 years of research by Canadian scientists. Clinical research shows that after oral administration these strains can colonize the vaginal tract and thus help the regeneration and maintenance of urovaginal health. Daily consumption of these probiotics constitutes a natural, safe and efficient help in protecting woman’s health.